6-OHDA HBr
featured

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 562486

CAS#: 636-00-0 (HBr)

Description: 6-OHDA HBr is a neurotoxin. It acts by destroying catecholaminergic terminals.


Chemical Structure

img
6-OHDA HBr
CAS# 636-00-0 (HBr)

Theoretical Analysis

MedKoo Cat#: 562486
Name: 6-OHDA HBr
CAS#: 636-00-0 (HBr)
Chemical Formula: C8H12BrNO3
Exact Mass: 249.0001
Molecular Weight: 250.09
Elemental Analysis: C, 38.42; H, 4.84; Br, 31.95; N, 5.60; O, 19.19

Price and Availability

Size Price Availability Quantity
5.0mg USD 210.0 2 Weeks
1.0g USD 1250.0 2 Weeks
2.0g USD 2250.0 2 Weeks
Bulk inquiry

Related CAS #: 1199-18-4 (free base)   636-00-0 (HBr)    

Synonym: 6-OHDA HBr; 6 OHDA HBr; 6OHDA HBr; 6-OHDA Hydrobromide; 6 OHDA Hydrobromide; 6OHDA Hydrobromide; 6-Hydroxydopamine Hydrobromide; 6Hydroxydopamine Hydrobromide; 6 Hydroxydopamine Hydrobromide; 6-Hydroxydopamine HBr; 6 Hydroxydopamine HBr;

IUPAC/Chemical Name: 2,4,5-Trihydroxyphenethylamine hydrobromide

InChi Key: MLACDGUOKDOLGC-UHFFFAOYSA-N

InChi Code: InChI=1S/C8H11NO3.BrH/c9-2-1-5-3-7(11)8(12)4-6(5)10;/h3-4,10-12H,1-2,9H2;1H

SMILES Code: NCCC1=CC(O)=C(O)C=C1O.[H]Br

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

Preparing Stock Solutions

The following data is based on the product molecular weight 250.09 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Deng QW, Yang H, Yan FL, Wang H, Xing FL, Zuo L, Zhang HQ. Blocking Sympathetic Nervous System Reverses Partially Stroke-Induced Immunosuppression but does not Aggravate Functional Outcome After Experimental Stroke in Rats. Neurochem Res. 2016 Aug;41(8):1877-86. doi: 10.1007/s11064-016-1899-8. Epub 2016 Apr 8. PubMed PMID: 27059792.

2: Nowak P, Kostrzewa RM, Kwieciński A, Bortel A, Labus Ł, Brus R. Neurotoxic action of 6-hydroxydopamine on the nigrostriatal dopaminergic pathway in rats sensitized with D-amphetamine. J Physiol Pharmacol. 2005 Jun;56(2):325-33. PubMed PMID: 15985712.

3: Sieroń A, Brus R, Szkilnik R, Plech A, Kubański N, Cieślar G. Influence of alternating low frequency magnetic fields on reactivity of central dopamine receptors in neonatal 6-hydroxydopamine treated rats. Bioelectromagnetics. 2001 Oct;22(7):479-86. PubMed PMID: 11568933.

4: Huang NY, Kostrzewa RM, Li C, Perry KW, Fuller RW. Persistent spontaneous oral dyskinesias in haloperidol-withdrawn rats neonatally lesioned with 6-hydroxydopamine: absence of an association with the Bmax for [3H]raclopride binding to neostriatal homogenates. J Pharmacol Exp Ther. 1997 Jan;280(1):268-76. PubMed PMID: 8996206.

5: Kostrzewa RM, Brus R, Perry KW, Fuller RW. Dopamine and 5-HT receptor sensitivity does not correlate with neostriatal dopamine or 5-HT content. Acta Neurobiol Exp (Wars). 1996;56(1):21-8. PubMed PMID: 8787176.

6: Plech A, Brus R, Kalbfleisch JH, Kostrzewa RM. Enhanced oral activity responses to intrastriatal SKF 38393 and m-CPP are attenuated by intrastriatal mianserin in neonatal 6-OHDA-lesioned rats. Psychopharmacology (Berl). 1995 Jun;119(4):466-73. PubMed PMID: 7480527.

7: Huang NY, Kostrzewa RM. Enhanced oral activity response to A77636 in neonatal 6-hydroxydopamine-lesioned rats. Eur J Pharmacol. 1994 Feb 21;253(1-2):163-6. PubMed PMID: 7912196.

8: Gong L, Kostrzewa RM, Perry KW, Fuller RW. Dose-related effects of a neonatal 6-OHDA lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Brain Res Dev Brain Res. 1993 Dec 17;76(2):233-8. PubMed PMID: 8149589.

9: Kostrzewa RM, Brus R, Perry KW, Fuller RW. Age-dependence of a 6-hydroxydopamine lesion on SKF 38393- and m-chlorophenylpiperazine-induced oral activity responses of rats. Brain Res Dev Brain Res. 1993 Nov 19;76(1):87-93. PubMed PMID: 8306435.

10: Gong L, Kostrzewa RM, Brus R, Fuller RW, Perry KW. Ontogenetic SKF 38393 treatments sensitize dopamine D1 receptors in neonatal 6-OHDA-lesioned rats. Brain Res Dev Brain Res. 1993 Nov 19;76(1):59-65. PubMed PMID: 8306431.

11: Gong L, Kostrzewa RM, Kalbfleisch JH. MIF-1 fails to modify agonist-induced oral activity in neonatal 6-OHDA-treated rats. Peptides. 1993 Nov-Dec;14(6):1159-64. PubMed PMID: 7907787.

12: Kostrzewa RM, Neely D. Enhanced pilocarpine-induced oral activity responses in neonatal 6-OHDA treated rats. Pharmacol Biochem Behav. 1993 Jul;45(3):737-40. PubMed PMID: 8332633.

13: Kostrzewa RM, Gong L, Brus R. Serotonin (5-HT) systems mediate dopamine (DA) receptor supersensitivity. Acta Neurobiol Exp (Wars). 1993;53(1):31-41. PubMed PMID: 8317265.

14: Gong L, Kostrzewa RM, Fuller RW, Perry KW. Supersensitization of the oral response to SKF 38393 in neonatal 6-OHDA-lesioned rats is mediated through a serotonin system. J Pharmacol Exp Ther. 1992 Jun;261(3):1000-7. PubMed PMID: 1602367.

15: Gong L, Kostrzewa RM. Supersensitized oral responses to a serotonin agonist in neonatal 6-OHDA-treated rats. Pharmacol Biochem Behav. 1992 Mar;41(3):621-3. PubMed PMID: 1584843.

16: Hamdi A, Kostrzewa RM. Ontogenic homologous supersensitization of dopamine D1 receptors. Eur J Pharmacol. 1991 Oct 2;203(1):115-20. PubMed PMID: 1839147.

17: Terry P, Stanford SC, Salmon P. Sympathoadrenal effects on extinction of rewarded running in the rat. Physiol Behav. 1991 Jun;49(6):1043-6. PubMed PMID: 1896487.

18: Ono H, Ito H, Fukuda H. 2-phenylethylamine and methamphetamine enhance the spinal monosynaptic reflex by releasing noradrenaline from the terminals of descending fibers. Jpn J Pharmacol. 1991 Mar;55(3):359-66. PubMed PMID: 1830350.

19: Salmon P, Stanford C. Peripheral noradrenaline depletion does not impair extinction of food-rewarded running in the rat. J Auton Nerv Syst. 1988 Jun;23(1):79-81. PubMed PMID: 3139736.

20: Yamada S, Yamamura HI, Roeske WR. Effects of chemical sympathectomy with 6-hydroxydopamine on alpha- and beta-adrenoceptors and muscarinic cholinoceptors in rat kidney. Eur J Pharmacol. 1986 Mar 4;121(3):345-53. PubMed PMID: 3009209.